• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Other Neurologic Disorders - Pipeline Review, H2 2012 Product Image

Other Neurologic Disorders - Pipeline Review, H2 2012

  • Published: December 2012
  • 45 pages
  • Global Markets Direct

Other Neurologic Disorders – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Other Neurologic Disorders - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Other Neurologic Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Other Neurologic Disorders. Other Neurologic Disorders - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Other Neurologic Disorders.
- A review of the Other Neurologic Disorders products READ MORE >

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Other Neurologic Disorders Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Other Neurologic Disorders 7
Other Neurologic Disorders Therapeutics under Development by Companies 9
Other Neurologic Disorders Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Discovery and Pre-Clinical Stage Products 14
Comparative Analysis 14
Other Neurologic Disorders Therapeutics – Products under Development by Companies 15
Other Neurologic Disorders Therapeutics – Products under Investigation by Universities/Institutes 16
Companies Involved in Other Neurologic Disorders Therapeutics Development 17
Biotie Therapies Corp. 17
Other Neurologic Disorders – Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Route of Administration 19
Assessment by Molecule Type 21
Drug Profiles 23
BTT-1023 - Drug Profile 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
lidocaine - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
methylprednisolone - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
rituximab - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Adult Human Mesenchymal Stem Cells - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
lithium carbonate - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
ALF-5755 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
NRG-101 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
gabapentin - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
brimonidine tartrate - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Other Neurologic Disorders Therapeutics – Drug Profile Updates 34
Other Neurologic Disorders Therapeutics – Discontinued Products 36
Other Neurologic Disorders Therapeutics - Dormant Products 37
Other Neurologic Disorders – Product Development Milestones 38
Featured News & Press Releases 38
Jul 01, 2011: Avanir Announces Paragraph IV ANDA Filing For NUEDEXTA 38
Mar 09, 2011: MediciNova Receives Notice Of Allowance For Method Of Treating Drug Addiction 38
Sep 14, 2010: AVANIR Announces Publication Of Results From AVP-923 Phase III Trial In Annals Of Neurology 39
Sep 01, 2010: Allergan Resolves United States Government Investigation of Past Sales and Marketing Practices Relating to Certain Therapeutic Uses of BOTOX 40
Jun 30, 2010: Chelsea Achieves Target Enrollment In Phase III Trial Of Northera In Neurogenic Orthostatic Hypotension 40
Jun 29, 2010: Chelsea Initiates Northera Study 306 In Neurogenic Orthostatic Hypotension Associated With Parkinson's Disease 41
Jun 01, 2010: Curemark Begins Enrollment For Autism Trials At Two More Sites 42
May 17, 2010: AVANIR Announces Zenvia Review Timeline Established By FDA With PDUFA Date Of October 30, 2010 42
Apr 30, 2010: AVANIR Submits Complete Response To FDA Approvable Letter For Zenvia In PBA 42
Apr 26, 2010: Curemark Begins Enrollment For Phase III Clinical Trials Of CM-AT At UC Davis MIND Institute 43
Appendix 44
Methodology 44
Coverage 44
Secondary Research 44
Primary Research 44
Expert Panel Validation 44
Contact Us 45
Disclaimer 45

List of Tables
Number of Products Under Development for Other Neurologic Disorders, H2 2012 7
Products under Development for Other Neurologic Disorders – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Late Stage Development, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Comparative Analysis by Early Clinical Stage Development, H2 2012 13
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 14
Products under Development by Companies, H2 2012 15
Products under Investigation by Universities/Institutes, H2 2012 16
Biotie Therapies Corp., H2 2012 17
Assessment by Monotherapy Products, H2 2012 18
Assessment by Stage and Route of Administration, H2 2012 20
Assessment by Stage and Molecule Type, H2 2012 22
Other Neurologic Disorders Therapeutics – Drug Profile Updates 34
Other Neurologic Disorders Therapeutics – Discontinued Products 36
Other Neurologic Disorders Therapeutics – Dormant Products 37

List of Figures
Number of Products under Development for Other Neurologic Disorders, H2 2012 7
Products under Development for Other Neurologic Disorders – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Late Stage Products, H2 2012 11
Mid Clinical Stage Products, H2 2012 12
Early Clinical Stage Products, H2 2012 13
Discovery and Pre-Clinical Stage Products, H2 2012 14
Assessment by Monotherapy Products, H2 2012 18
Assessment by Route of Administration, H2 2012 19
Assessment by Stage and Route of Administration, H2 2012 20
Assessment by Molecule Type, H2 2012 21
Assessment by Stage and Molecule Type, H2 2012 22

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos